Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1314

Sort by

Sort Order Select

Journal Articles

Mental Health and Treatment in Patients with Immune Thrombocytopenia (ITP); Data from the Platelet Disorder Support Association (PDSA) Patient Registry

Alexandra Kruse, Caroline Kruse, Nancy Potthast, Kelsey Milligan, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 2362.

https://doi.org/10.1182/blood-2019-122278

Published: 2019

Journal Articles

The Oxygenscan Provides Clinically Relevant Biomarkers for Treatment Efficacy That Are Associated with Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease

Minke A.E. Rab, MD, Richard van Wijk, PhD, Celeste K. Kanne, BA, Brigitte A. van Oirschot, Jennifer Bos, Camille Boisson, Maite E. Houwing, MD, Jorn J. Gerritsma, MD, Karin Fijnvandraat, MD PhD, Celine Renoux, PhD, Marije Bartels, MD PhD, Erfan Nur, MD PhD, Marjon H. Cnossen, MD PhD, Philippe Joly, PhD, Romain Fort, MD, Philippe Connes, PhD, Eduard J. van Beers, MD PhD, Vivien A. Sheehan, MD PhD

Blood (2019) 134 (Supplement_1): 2275.

https://doi.org/10.1182/blood-2019-128870

Published: 2019

Journal Articles

Is It Necessary to Combine Glucocorticoid in Newly Diagnosed ITP Infant Under 1 Year-Old with Severe Thrombocytopenia When Based on Intravenous Immunoglobulin Treatment ?

Shayi Jiang, MD, Eric S. Sandler, MD, Hui Jiang, PhD

Blood (2019) 134 (Supplement_1): 2368.

https://doi.org/10.1182/blood-2019-124827

Published: 2019

Journal Articles

Treatment of Delayed Hemolytic Transfusion Reactions in Sickle Cell Disease Patients By an Anti-C5 Antibody

Blood (2019) 134 (Supplement_1): 2458.

https://doi.org/10.1182/blood-2019-127176

Published: 2019

Journal Articles

Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen

Blood (2019) 134 (Supplement_1): 463.

https://doi.org/10.1182/blood-2019-127811

Published: 2019

Journal Articles

Mitigation of Vascular Permeability Using Bradykinin Receptor Antagonist and Anti-Fibrinolytic Agent in Rats with Polytrauma and Hemorrhagic Shock

Xiaowu Wu, MD MSc, Daniel N. Darlington, PhD, Josue Garciamarcano, Bin Liu, BS, Jeffrey D Keesee, BS, James Bynum, PhD, Andrew P. Cap, MD PhD

Blood (2019) 134 (Supplement_1): 2345.

https://doi.org/10.1182/blood-2019-130278

Published: 2019

Journal Articles

Combined Modality Low-Dose Radiation Therapy (2 Gy x 2) and Single-Agent Rituximab Immunotherapy in the Treatment of Indolent Non-Hodgkin Lymphoma

Samantha Brocklehurst, Neil Desai, MD MHS, Jennifer L Shah, MD, Syed Rizvi, MD, Praveen Ramakrishnan Geethakumari, MD, Kiran A Kumar, MD MBA

Blood (2019) 134 (Supplement_1): 5262.

https://doi.org/10.1182/blood-2019-131246

Published: 2019

Journal Articles

Efficacy Analysis of Ruxolitinib in Treatment of 72 Patients with Myelofibrosis in a Chinese Institution

Yunfan Yang, MD, Zhongqing Zou, MD, Ting Liu, MD PhD, Yongqian Jia, PhD, Ting Niu, MD PhD, Huanling Zhu, MD, Yu Wu, MD, Yuping Gong, MD, Hong Chang, MD, Jie Ji, MD, Jian Li, MD, Ling Pan

Blood (2019) 134 (Supplement_1): 5384.

https://doi.org/10.1182/blood-2019-128553

Published: 2019

Journal Articles

High Risk DLBCL in Younger Patients: Should ASCT be Declined in the Era Pos-Rituximab?

Miguel Quintela, Iolanda Vieira, Cláudia Moreira, Sérgio Chacim, Nelson Domingues, Isabel Oliveira, Ana Espirito Santo, Maria Ilidia Moreira, Ângelo Martins, Maria Luisa Viterbo, Dulcineia Pereira, Jose Mario Mariz

Blood (2019) 134 (Supplement_1): 5356.

https://doi.org/10.1182/blood-2019-131254

Published: 2019

Journal Articles

Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment

Yandong Shen, BMedSc (Hon) PhD, Kyle R Crassini, MBBS,BSc, Narjis Fatima, BSMedTech,MPhil, Richard Christopherson, PhDEmeritus Professor, Stephen P. Mulligan, PhDFRACP,FRCPA,MBBS, Oliver Giles Best, PhDBSc

Blood (2019) 134 (Supplement_1): 5443.

https://doi.org/10.1182/blood-2019-130082

Published: 2019

Journal Articles

Response to Brentuximab Vedotin and Quality of Life in Patients with Relapsed/Refractory Hodgkin Lymphoma (RR HL) in the Real World Setting

Blood (2019) 134 (Supplement_1): 5296.

https://doi.org/10.1182/blood-2019-121997

Published: 2019

Journal Articles

Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study

Blood (2019) 134 (Supplement_1): 5476.

https://doi.org/10.1182/blood-2019-126402

Published: 2019

Journal Articles

Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

Claire N Harrison, Professor, Aaron T. Gerds, MD MS, Jean-Jacques Kiladjian, MD PhD, Konstanze Döhner, Sarah A Buckley, MD, Jennifer A. Smith, PhD, Adam R Craig, MD PhD, John Mascarenhas, MD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4175.

https://doi.org/10.1182/blood-2019-129245

Published: 2019

Journal Articles

Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Guillermo Garcia-Manero, MD, Ghulam J. Mufti, Pierre Fenaux, MD PhD, Rena Buckstein, MD FRCPC, Valeria Santini, MD, María Díez-Campelo, MD PhD, Carlo Finelli, Mario Cazzola, MD, Osman Ilhan, Mikkael A. Sekeres, MD MS, Alan F. List, MD, Abderrahmane Laadem, Rodrigo Ito, Jennie Zhang, Anita Rampersad, Daniel Sinsimer, Peter G. Linde, Uwe Platzbecker, MD, Rami Komrokji

Blood (2019) 134 (Supplement_1): 4243.

https://doi.org/10.1182/blood-2019-123048

Published: 2019

Journal Articles

The Role of Demographic and Social Factors on Decision Making in Patients with Relapsed and Refractory Multiple Myeloma Treated By Ixazomib, Lenalidomide and Dexamethasone

Jiri Minarik, MD PhD, Alexandra Jungova, Jan Straub, MD, Evzen Gregora, MD, Jana Bryknarova, Blanka Nemcova, Roman Hajek, MD

Blood (2019) 134 (Supplement_1): 5832.

https://doi.org/10.1182/blood-2019-130961

Published: 2019

Journal Articles

Follicular Lymphoma Frontline Immuno-Chemotherapy: Survival Outcomes and Infection-Related Morbidity

Faouzi Djebbari, Furqaan Kaji, Louise Stanton, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Toby A. Eyre

Blood (2019) 134 (Supplement_1): 5884.

https://doi.org/10.1182/blood-2019-122213

Published: 2019

Journal Articles

Cost-Effectiveness Model of Recombinant FVIII Versus Emicizumab Treatment of Patients With Severe Hemophilia A Without Inhibitors

Shawn X. Sun, Yanyu Wu, Michael McDermott, Marjolijn van Keep

Blood (2019) 134 (Supplement_1): 2102.

https://doi.org/10.1182/blood-2019-124421

Published: 2019

Journal Articles

Allogeneic Stem Cell Transplantation Combined with Mesenchymal Stem Cells Transfusion in Primary Myelofibrosis-a Single-Center Retrospective Study

Qingyuan Wang, MD, Limin Liu, MD PhD, Huifen Zhou, Miao Miao, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 2054.

https://doi.org/10.1182/blood-2019-130572

Published: 2019

Journal Articles

Efficacy of Allogeneic Hematopoietic Cell Transplantation (HCT) in Sickle Cell Disease: Results of a Systematic Review/Meta-Analysis

Madiha Iqbal, MBBS, Tea Reljic, MPH, Ernesto Ayala, MD, Hemant S. Murthy, MD, Ambuj Kumar, MD MPH, Mohamed A Kharfan-Dabaja, MDMBA

Blood (2019) 134 (Supplement_1): 2106.

https://doi.org/10.1182/blood-2019-124955

Published: 2019

Journal Articles

Cord Blood Transplantation Is an Effective Treatment Option in Patients with Myelodysplastic and Myeloproliferative Syndromes

Laura Roberts, Rachel B. Salit, MD, Lauren Longo, Elisabetta Xue, MD, Corinne Summers, MD, Colleen Delaney, MD MSc, Ann Dahlberg, MD, Filippo Milano, MD PhD

Blood (2019) 134 (Supplement_1): 2048.

https://doi.org/10.1182/blood-2019-126216

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Mental Health and Treatment in Patients with Immune Thrombocytopenia (ITP); Data from the Platelet Disorder Support Association (PDSA) Patient Registry

The Oxygenscan Provides Clinically Relevant Biomarkers for Treatment Efficacy That Are Associated with Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease

Is It Necessary to Combine Glucocorticoid in Newly Diagnosed ITP Infant Under 1 Year-Old with Severe Thrombocytopenia When Based on Intravenous Immunoglobulin Treatment ?

Treatment of Delayed Hemolytic Transfusion Reactions in Sickle Cell Disease Patients By an Anti-C5 Antibody

Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen

Mitigation of Vascular Permeability Using Bradykinin Receptor Antagonist and Anti-Fibrinolytic Agent in Rats with Polytrauma and Hemorrhagic Shock

Combined Modality Low-Dose Radiation Therapy (2 Gy x 2) and Single-Agent Rituximab Immunotherapy in the Treatment of Indolent Non-Hodgkin Lymphoma

Efficacy Analysis of Ruxolitinib in Treatment of 72 Patients with Myelofibrosis in a Chinese Institution

High Risk DLBCL in Younger Patients: Should ASCT be Declined in the Era Pos-Rituximab?

Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment

Response to Brentuximab Vedotin and Quality of Life in Patients with Relapsed/Refractory Hodgkin Lymphoma (RR HL) in the Real World Setting

Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study

Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

The Role of Demographic and Social Factors on Decision Making in Patients with Relapsed and Refractory Multiple Myeloma Treated By Ixazomib, Lenalidomide and Dexamethasone

Follicular Lymphoma Frontline Immuno-Chemotherapy: Survival Outcomes and Infection-Related Morbidity

Cost-Effectiveness Model of Recombinant FVIII Versus Emicizumab Treatment of Patients With Severe Hemophilia A Without Inhibitors

Allogeneic Stem Cell Transplantation Combined with Mesenchymal Stem Cells Transfusion in Primary Myelofibrosis-a Single-Center Retrospective Study

Efficacy of Allogeneic Hematopoietic Cell Transplantation (HCT) in Sickle Cell Disease: Results of a Systematic Review/Meta-Analysis

Cord Blood Transplantation Is an Effective Treatment Option in Patients with Myelodysplastic and Myeloproliferative Syndromes

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only